| Patient | Barbara Jordan |
|---|---|
| Date of birth | 1982-02-21 |
| Identifiers | MRN HR-ML030-SYN; SSN (made up) 000-30-6852 |
| Document date | 2026-04-20 |
| Author | Evangeline Moss, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Five-week review: second vaccine doses, baclofen titration, physical therapy, and readiness for the first infusion. [S]
Ms. Jordan returns five weeks after the consultation. Baclofen 5 mg three times a day made her drowsy for the first week; this has passed, and her mornings are less stiff. Mirabegron has helped: she now gets up once most nights. She had a sore arm for a day after the vaccines and no other reaction. She has had no new symptoms and no infection. The physical therapy evaluation requested at intake has not happened: the clinic's therapist with experience in multiple sclerosis has a waiting list, and she has not yet been offered a date. Her employer has agreed to the accommodations she asked for. She would like the infusions on days without teaching. [S]
| Element | Detail |
|---|---|
| Baclofen | Drowsy the first week, now settled; stiffness better |
| Bladder | Up once most nights on mirabegron |
| Physical therapy | Not yet seen; waiting list |
| Work | Accommodations agreed |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or infection |
| Genitourinary | Negative | Urgency better; no burning |
| Musculoskeletal | Positive | Mild morning stiffness |
| Neurological | Negative | No new numbness, weakness or visual change |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol (vitamin D3) 2000 units (50 mcg) oral capsule, one capsule daily | One capsule daily | Oral route | 2026-03-02 | active | S |
| Baclofen 5 mg oral tablet, one tablet three times a day, to be increased to 10 mg three times a day once tolerated | One tablet three times a day | Oral route | 2026-03-16 to 2026-04-20 | completed | S |
| Baclofen 10 mg oral tablet, one tablet three times a day | One tablet three times a day | Oral route | 2026-04-20 | active | S |
| Mirabegron 25 mg extended-release oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-16 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-20 | Body height | 173 | cm | S |
| 2026-04-20 | Body weight | 83.8 | kg | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 28 | kg/m2 | S |
| 2026-04-20 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-04-20 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-04-20 | Heart rate | 72 | /min | S |
| 2026-04-20 | Respiratory rate | 16 | /min | S |
| 2026-04-20 | Body temperature | 36.6 | Cel | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
Vital signs recorded on 2026-04-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 120/76, pulse 72; temperature 36.6 °C |
| Neurological | Gait unchanged with a cane; modified Ashworth 1+ in both legs; hip flexor strength 4 out of 5, unchanged with baclofen |
| Skin | No rash; vaccine sites healed |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Multiple sclerosis diagnosed elsewhere, by her account, with records of the original evaluation not available: slowly worsening walking over the past few years, leg stiffness, fatigue, urinary urgency and heat sensitivity; uses a cane; course to be classified after MRI of the brain and spine | resolved | confirmed | G35.D | S — Synthetic presenting picture at intake, superseded by the classified diagnosis at the consultation; the cane and a diagnosis around the time she left Congress are from public accounts. |
| Active primary progressive multiple sclerosis: gradual worsening of walking over more than a year without relapses, with brain lesions in periventricular, juxtacortical and infratentorial regions, three spinal cord lesions, and one gadolinium-enhancing lesion; fulfils the 2017 McDonald criteria for primary progressive disease; EDSS 6.0; synthetic modern detail linked to her publicly reported multiple sclerosis | active | confirmed | G35.B1 | S — Synthetic course, MRI findings and disability score; the disease itself and her use of a cane are from public accounts. |
| Spastic gait from multiple sclerosis, walking with a cane, with two near-falls and no falls in the past year; at risk of falls | active | confirmed | R26.89 | S — Synthetic modern coding anchored to her documented cane. |
| Neurogenic bladder from multiple sclerosis: urgency and getting up twice at night, with a low post-void residual | active | confirmed | N31.9 | S — Synthetic; common in multiple sclerosis. No public source describes her bladder. |
| Vitamin D deficiency | active | confirmed | E55.9 | S — Synthetic laboratory finding at intake. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | New or worsening symptoms (relapse, pseudo-relapse with heat or infection) | Every visit | Completed today | No new symptoms |
| Examination | Disability: EDSS and timed 25-foot walk | Every visit, and at least every 6 months | Up to date | EDSS 6.0 five weeks ago; gait unchanged today |
| Imaging | Brain MRI | At diagnosis with gadolinium; re-baseline 3 to 6 months after starting therapy; then yearly without routine gadolinium | Up to date | Diagnostic MRI five weeks ago; re-baseline due three to six months after the first dose |
| Medication safety | Vaccines before therapy (PCV20, recombinant zoster x2, Tdap, hepatitis B x2) | Inactivated at least 2 weeks and live at least 4 weeks before the first dose | Completed today | Zoster dose 2 and hepatitis B dose 2 today; series complete; first infusion two weeks from today |
| Medication safety | Infusion reactions and infections | Each infusion, and every visit | Completed today | No infection today; premedication and observation planned |
| Examination | Spasticity (modified Ashworth) and baclofen tolerance | Every visit | Completed today | Modified Ashworth 1+; baclofen increased to 10 mg three times a day |
| Examination | Bladder: urgency, nocturia, urinary infection, and blood pressure on mirabegron | Every visit | Completed today | Nocturia once; blood pressure 120/76 on mirabegron |
| Referral | Falls, walking aids and physical therapy | Every visit | Deferred | Missed: the physical therapy evaluation requested at intake has not happened because of a waiting list. No harm so far: no falls and her gait is unchanged. Corrective action: the clinic asked the service today for the first available date, with a second provider if none is offered within three weeks; daily stretching and home exercises meanwhile |
| Self-management | Workplace accommodation | At intake and with any change | Completed today | Accommodations agreed by her employer |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2; Recombinant zoster vaccine, dose 2 of 2 [S]
Guideline basis: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021); Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019); OCREVUS (ocrelizumab) injection, prescribing information (2026); Multiple sclerosis in adults: management (NG220) (2022); Accommodation and Compliance: Multiple Sclerosis (2026); Introduction to the Americans with Disabilities Act (2026); Adult Immunization Schedule by Age (2026); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026)
Follow-up: Ocrelizumab infusions in two and four weeks at the infusion center. Review six weeks after the second infusion with a blood count, CD19 count, vitamin D and the PHQ-9. Next scheduled visit 2026-06-29: four-month review, six weeks after the first ocrelizumab doses: infusion tolerance, infections, blood counts, vitamin D, heat and mood. [S]